Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)
Authors
Hanna, C. R.O'Cathail, S. M.
Graham, J. S.
Saunders, Mark P
Samuel, L.
Harrison, M.
Devlin, L.
Edwards, J.
Gaya, D. R.
Kelly, C. A.
Lewsley, L. A.
Maka, N.
Morrison, P.
Dinnett, L.
Dillon, S.
Gourlay, J.
Platt, J. J.
Thomson, F.
Adams, R. A.
Roxburgh, C. S. D.
Affiliation
Cancer Research UK Glasgow Clinical Trials Unit, Beatson West of Scotland Cancer Centre, Institute of Cancer Sciences, University of Glasgow, Level 0, 1053 Great Western Road, Glasgow, G12 0YN, UK.Issue Date
2021
Metadata
Show full item recordCitation
Hanna CR, O’Cathail SM, Graham JS, Saunders M, Samuel L, Harrison M, et al. Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT) Vol. 16, Radiation Oncology. Springer Science and Business Media LLC; 2021.Journal
Radiotherapy and OncologyDOI
10.1186/s13014-021-01941-zPubMed ID
34857017Type
Otherae974a485f413a2113503eed53cd6c53
10.1186/s13014-021-01941-z